Regulatory Exclusivity Expiring in 2025
✉ Email this page to a colleague
Drugs with Regulatory Exclusivity Expiring in 2025
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|
Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Try for Free | NEW PATIENT POPULATION | |
Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-002 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Try for Free | NEW PATIENT POPULATION | |
Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-003 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Try for Free | NEW PATIENT POPULATION | |
Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-004 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Try for Free | NEW PATIENT POPULATION | |
Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-005 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Try for Free | NEW PATIENT POPULATION | |
Urovant | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | ⤷ Try for Free | NEW CHEMICAL ENTITY | |
Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ⤷ Try for Free | PEDIATRIC EXCLUSIVITY | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |